A5080737820- Cancer Immunotherapy and Biomarkers
- Colorectal and Anal Carcinomas
- Head and Neck Cancer Studies
- Cancer Genomics and Diagnostics
- Advanced Breast Cancer Therapies
- NF-κB Signaling Pathways
- Breast Cancer Treatment Studies
- Cancer Diagnosis and Treatment
- Lung Cancer Treatments and Mutations
- Cancer-related Molecular Pathways
- Cancer therapeutics and mechanisms
- Immunotherapy and Immune Responses
- HER2/EGFR in Cancer Research
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Research Studies
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
AstraZeneca (United Kingdom)
2022-2024
Abstract Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in ER+ breast cancer (BC) the Phase 1 SERENA-1 study1,2 with dose-dependent safety profile. The 2 randomized SERENA-2 study (NCT04214288) initially assessed three doses of C vs fulvestrant (F) post-menopausal women HER2˗ BC disease recurrence or progression after ≤1 endocrine therapy (ET) advanced setting. Methods evaluated...
Abstract Purpose: Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response improve outcomes recurrent/metastatic HPV-16/18–associated HNSCC. Patients Methods: In this phase Ib/IIa study, immunotherapy-naïve patients ≥1 previous...
TPS3156 Background: The epidermal growth factor receptor (EGFR) and mesenchymal-epidermal transition tyrosine kinase (c-MET) are expressed in diverse solid tumors, function as driver genes some types. Clinical benefit of bispecific monoclonal antibodies (Ab) targeting these receptors was demonstrated pts with EGFR mutated (EGFRm) non-small-cell lung cancer (NSCLC), but an ADC has not been developed. AZD9592 is a Ab c-MET. When internalized, releases topoisomerase 1 inhibitor (TOP1i) warhead...
TPS8130 Background: Small-cell lung cancer (SCLC) is the most fatal type of characterized by exquisite chemo-sensitivity at diagnosis and chemoresistance relapse. Despite a highly mutated genome, patients with SCLC derive little benefit from immunotherapy. EZH2 (enhancer zeste homolog 2) master epigenetic regulator neuroendocrine cell fate plasticity. inhibition 1) promotes upregulation Schlafen 11 (SLFN11) which irreversibly blocks replication in response to DNA damaging agents enhances...
<div>AbstractPurpose:<p>Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response improve outcomes recurrent/metastatic HPV-16/18–associated HNSCC.</p>Patients Methods:<p>In this phase Ib/IIa study,...
<p>Supplementary Figure S1. Patient disposition. Supplementary S2. Association of PD-L1 expression and HPV status with best antitumor response. S3. Kaplan-Meier distribution curves for (A) PFS (B) OS in the as-treated population according to line treatment platinum-refractory status, including estimates medians. S4. Peripheral HPV-18-specific T-cells on IFNγ ELISpot assay PMBCs. S5. HPV-16 (A, C) E6-specific (B, D) E7-specific T-cell responses S6. HPV-18 S7. Baseline peripheral...
<p>Supplementary Figure S1. Patient disposition. Supplementary S2. Association of PD-L1 expression and HPV status with best antitumor response. S3. Kaplan-Meier distribution curves for (A) PFS (B) OS in the as-treated population according to line treatment platinum-refractory status, including estimates medians. S4. Peripheral HPV-18-specific T-cells on IFNγ ELISpot assay PMBCs. S5. HPV-16 (A, C) E6-specific (B, D) E7-specific T-cell responses S6. HPV-18 S7. Baseline peripheral...
<div>AbstractPurpose:<p>Tumoral programmed cell death ligand-1 (PD-L1) expression is common in human papillomavirus (HPV)–associated head and neck squamous carcinoma (HNSCC). We assessed whether a DNA vaccine targeting HPV-16/18 E6/E7 with IL12 adjuvant (MEDI0457) combined the PD-L1 inhibitor durvalumab could enhance HPV-specific T-cell response improve outcomes recurrent/metastatic HPV-16/18–associated HNSCC.</p>Patients Methods:<p>In this phase Ib/IIa study,...